The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Trial Details

NCT ID
NCT05502523
Phase
NA
Sponsor
Thomas Jefferson University
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Pulmonary Artery-First Surgical Technique
  • Biospecimen Collection
Locations (sample)
  • Abington, Pennsylvania, United States|40.12067,-75.11795
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Willow Grove, Pennsylvania, United States|40.144,-75.11573

Key Eligibility Criteria

  • Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
  • Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →